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Abstract 
Fluorinated nucleosides constitute a large class of chemotherapeutics approved for clinical use. The 
pharmacokinetic and pharmacodynamic properties of a drug can be affected, as a consequence of 
modulation of electronic, lipophilic and steric parameters, by the introduction of fluorine into the 
structure of drug-like molecule. Herein, we focus on fluorinated-nucleoside analogs, their therapeutic 
use and applications based on the patent literature from 2014 to 2018. We briefly discuss the clinical 
properties of anticancer and antiviral fluorine-containing nucleos(t)ides FDA-approved or in 
development, and highlight their resistance mechanisms and limitations in the clinic. We emphasize 
patent inventions related to improved synthetic methods towards selected nucleos(t)ide analogs 
including the phosphoramidate sofosbuvir and 18F-labelled nucleosides FLT and FMAU, used as a 
18F-PET tracers. 
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Introduction 
 
Fluorine organic chemistry plays a significant role in a number of different research fields. During 
the last three decades, fluoro-organic chemistry has become a research area of high interest, in 
particular for several different drug discovery programs. Fluorine insertion in the structures of 
bioactive organic molecules has effects on several molecular properties such as electronics, 
occupational volume and lipophilicity, this way affecting pharmacodynamic and pharamacokinetic 
features of drug-like compounds. Hydrogen replacement with fluorine can remove a potential 
oxidative site for drug metabolism, thus avoiding the production of unwanted metabolites [1,2].  
Fluorine also has a very important function in positron emission tomography (PET), thanks to the 
favourable, relatively short half-life of its radioisotope 18F (109.8 min), which makes possible to 
synthesise the tracer and carry out the imaging process within few hours. Moreover, the use of 18F is 
advantageous for imaging, as it gives good spatial resolution, due to its nature of low positron 
emission energy emitter. As 18F is the optimal radioisotope for PET, many research efforts have been 
directed towards the development of efficient pathways for the synthesis of new 18F-PET tracers. 
Currently, several 18F-nucleoside analogs are being explored in clinical trials as proliferation 
biomarkers, as predictive tools for the patient’s response to chemotherapy with nucleoside analogs, 
and as reporter imaging probes for the development of individually personalised medicines [3]. 
However, the synthesis of such NAs is challenging as the insertion of 18F-fluorine into NAs should 
preferably be at a late synthetic stage, in a way that allows for the synthetic routes to prepare the 
labelled NAs and the imaging process to take place within several half-lives, in order to provide 
scanning data of high quality. The focus of this review will be several methods for the synthesis of 
fluorinated nucleoside analogs and their biological application based on the most recent patent 
literature published between 2014 and 2018. We will discuss an improved chemo-enzymatic method 
for the preparation of clofarabine, an established anticancer agent, and radio-synthesis methods 
towards 18F-radiolabeled nucleoside analogs exemplified herein by [18F]-FLT and [18F]-FMAU. We 
will cover the most recent inventions related to improved synthetic methods for the preparation of 
sofosbuvir parent nucleoside 2’-deoxy-2’-fluoro-2’-C-methyluridine and sofosbuvir, and highlight 
patent applications disclosing procedures with novel intermediates used for the synthesis of this 
blockbuster anti-HCV agent. Furthermore, miscellaneous applications of fluorinated nucleosides will 
be exemplified by RNA interference agents (RNAi), amphiphilic glycosyl nucleosides and 
deoxyribocyclic dinucleotides used as modulators of gene expression, supramolecular systems 
suitable for decontamination of aqueous mediums, and as activators of the STING receptor.  
 
Anticancer fluorinated nucleoside analogs 
 
An important family of FDA-approved drugs is comprised of fluorine-containing nucleoside analogs 
(NAs). Similarly to other modified NAs, fluorinated nucleosides mimic natural nucleosides in terms 
of their cellular uptake and metabolism. Their biological activity is exhibited most often through the 
action of 5’-triphosphate metabolites. These active species are formed, after nucleoside transport-
mediated uptake, via an intracellular step-wise phosphorylation. NAs in their active-phosphorylated 
forms can suppress cell growth and division by inhibition of de novo synthesis of DNA and RNA 
precursors [4] as well as by inhibition of intracellular enzymes such as human or viral polymerases, 
ribonucleotide reductase (RNR) [5] and thymidylate synthase (TS) [6]. Anticancer fluorinated 
nucleoside analogs are represented by 5-fluorouracil (5-FU, 1), which is one of the first anticancer 
drugs ever approved by FDA, and it is part of the essential medicines present in WHO list (Figure 1). 
5-FU, together with its 2’-deoxy ribose analog 5-fluoro-2’-deoxyuridine (FUDR, 2) is approved and 
currently used to treat solid tumours, including gastric, colon, breast and ovarian carcinomas. The 
main mechanism through which 1 and 2 exert their biological activity is demonstrated at the level of 
5’-monophosphate form by targeting thymidine synthase (TS). The TS enzyme is trapped in a ternary 
complex (TS/FdUMP/mTHF), thus irreversibly losing its enzymatic activity. As a consequence, 
further formation of thymidine monophosphate (TMP), which represents an essential component for 
the processes of DNA synthesis and repair, is altered [7,8]. 5-FU can also be incorporated into RNA 
and thus disrupt normal RNA processing and functions [9,10]. The effectiveness of 5-FU, as well as 
clinically approved NAs in general, is reduced by the insurgence of resistance, which can occur 
according to different mechanisms: decreased cellular uptake via nucleoside-specific transporters, 
reduced conversion to the active 5’-monophosphate form, carried out by thymidine kinase, or less 
efficient inhibition of TS (as in case of 1) [11-13], and/or up-regulation of deactivating enzymes (i.e 
nucleo(s)(t)ide deaminases, purine/pyrimidine nucleoside phosphorylase) [14,15]. In this view, a 
number of 5-FU prodrugs including capecitabine (3) have been designed in order to overcome the 
main resistance mechanisms and are at present either approved for clinical use or under clinical 
investigation [16,17]. Capecitabine is considered as an extremely important pro-drug of 1 and it is 
used as a front-line chemotherapy agent to treat patients with metastatic colorectal cancer and 
metastatic breast cancer resistant to paclitaxel and anthracycline [18]. 
 
Figure 1. FDA-approved anticancer fluorinated nucleos(t)ide analogs and selected examples of 
fluorinated agents in advanced stages of clinical trials.  
 Gemcitabine (4) is another fluorinated nucleoside analog used in the treatment of solid tumours 
including pancreatic, non-small-cell lung, ovarian, bladder and breast cancers. The active 5’-
triphosphate form (dFdC-TP) of 4 is incorporated in the cellular DNA during the S-phase of the cell 
life cycle, causing termination of nucleic acid synthesis, thus leading to cell death. Additionally, the 
5’-diphosphate form of gemcitabine (dFdC-DP) inhibits ribonucleotide reductase (RNR), an enzyme 
that catalyses the formation of deoxyribonucleotides from ribonucleotides essential for DNA 
synthesis and repair [19,20]. To improve the efficacy of 4, and particularly to have an increased 
intracellular formation of its active metabolite (dFdC-TP), to yield an increased half-life in the 
systemic circulation, to reduce the susceptibility to inactivation by cytidine deaminase, and to increase 
overall bioavailability, the 4-(N) and/or 5’-sites of gemcitabine have been extensively modified, for 
example with the phosphoramidate approach, leading to a number of agents in clinical development 
such as the L-alanine based-ProTide NUC-1031 (9) (Figure 1), extensively reviewed in the literature 
[13,15,21,22]. Trifluorothymidine (TFT, 5) is a nucleoside analogue with a CF3 group at the 5-
position of the nucleobase. TFT is phosphorylated inside the cell by thymidine kinase to the active 
5’-monophosphate form (TFT-MP), which is a reversible inhibitor of the thymidylate synthase (TS) 
enzyme. This action is exerted by TFT-MP through reversible binding to the enzyme active pocket 
[23].  TFT-MP undergoes further phosphorylation to its 5’-diphosphate (TFT-DP) and 5’-triphosphate 
(TFT-TP) forms. TFT-TP is incorporated into DNA growing strands of cells, causing the induction 
of nucleic acid fragmentation [24,25]. In 2015, a combination of tipiracil hydrochloride, a thymidine 
phosphorylase inhibitor used in chemotherapy, and TFT was approved as TAS-102, to treat refractory 
colorectal cancer. RX-3117 (8) is a cytosine analog of the natural nucleoside neplanocin A, 
characterised by the presence of a fluorinated cyclopentenyl function to replace the ribose sugar 
(Figure 1) [26-28]. RX-3117 is orally available and effective as an anticancer in several different 
human tumour xenografts. A first completed clinical trial using RX-3117 as monotherapy in patients 
with solid tumours has shown promising indications of safety and tolerability [29].  
Among purine nucleosides, fluorinated adenosine analogs represented by fludarabine (6) and 
clofarabine (7) have acquired a solid position in the treatment of hematologic malignancies. 
Fludarabine is a clinically approved agent for the treatment of chronic lymphocytic leukemia (CLL) 
and acute myelogenous leukemia (AML) [30]. Fludarabine active metabolite, its 5’-triphosphate form 
(F-ara-ATP), is an inhibitor of DNA polymerases and also of other enzymes essential for the synthesis 
of cellular DNA, including the DNA primase, DNA ligase and ribonucleotide reductase [31-33]. 
Clofarabine is used to treat patients affected by relapsed and refractory paediatric acute lymphoblastic 
leukemias, and it is also under clinical investigation, in combination with other agents, to treat chronic 
lymphocytic leukemia, acute myelogenous leukemia and myelodysplastic syndrome [34,35]. The 
anticancer activity of clofarabine is achieved via three major mechanisms, and these include 
inhibition of ribonucleotide reductase (RNR), inhibition of DNA synthesis, and direct induction of 
apoptosis [36]. Furthermore, clofarabine was also reported to be involved in the inhibition of the 
polyadenylation process that is considered to be an essential step in cells to synthesise and maintain 
transcripts of mRNA [37]. Interestingly, clofarabine was recently demonstrated to act as an inhibitor 
of HIV-1 replication by exerting a dual action: first, this nucleoside analog reduces the dNTP 
substrates pool available to the virus to synthesise its DNA, and second it inhibits the DNA 
polymerase activity of the viral reverse transcriptase enzyme [38].  
 
Anticancer nucleosides containing fluorine or methods for their preparation in recent patent 
literature 
Among different synthetic strategies for the preparation of nucleoside analogs including fluorine-
containing nucleosides, N-glycosylation represents the mildest and most commonly applied method 
[39,40]. It involves a reaction between (fluorinated) sugar and nucleobase moieties in the presence of 
a Lewis acid, typically SnCl4 or TMSOTf [41]. However, depending on the starting materials used in 
the reaction (nucleobase and sugar), the regio- and stereoselectivity of the N-glycosylation can prove 
challenging, as it often leads to complex mixtures of products. Introduction of fluorine into 
nucleosides can be achieved either via nucleophilic or electrophilic fluorination using fluorinating 
agents such as Olah’s reagents, DAST and XtalFluor-E or Selectfluor [42-44]. An extensive review 
on synthetic methodologies for the preparation of antitumour fluorinated nucleobase 5-fluorouracil 
(1), and its nucleoside-derivatives including FUDR (2), capecitabine (3), as well as pyrimidine 
nucleosides fluorinated at the sugar moiety such as gemcitabine (4) and related non-clinical 
nucleosides, was recently published by Ferraboschi and colleagues [45]. 
A recent improved method for the preparation of anticancer agent clofarabine (7) has been filed in 
April 2014 (date of second filling April 2015) by Synbias Pharma AG, and consists of a number of 
steps including an enzymatic trans-glycosylation between 2-chloroadenine (12) and appropriate 
nucleosides followed by benzoylation, isomerization, sulfonylation, fluorination and deprotection 
steps [46,47]. The key enzymatic trans-glycosylation step between 2-chloroadenine and either uridine 
or guanosine as nucleosides was performed with purine nucleoside phosphorylase (PNP) or a 
combination of uridine phosphorylase (UP) and PNP [48]. The trans-glycosylation allowed a 
formation of only desired β-N9-stereoisomers, thus avoiding major disadvantages of traditional 
procedures and providing more efficient, less laborious synthetic procedures with high yield of 
product formation (overall yield 32% after 6 steps). The crucial fluorination step is performed with a 
mixture of hydrofluoric acid and an organic Lewis base. The authors compare their invention (Figure 
2) with the main and established in the art synthetic methods (a) convergent: comprising generally of 
a coupling reaction between the purine derivatives and a fluorinated-arabinofuranosyl moiety [49-
52], and (b) divergent: consisting of the introduction of fluorine into a pre-formed nucleoside analog 
by chemical transformations [53]. All the above-mentioned established methods have some 
disadvantages associated with either i) low stability of the starting material (fluorinated sugar); ii) 
challenging separation of the coupling product from the number of isomers (β-N9, α-N7, β-N7) 
formed during the reaction. In this view, the chemo-enzymatic method for the preparation of 
clofarabine can be considered as more advantageous over these previously reported procedures, 
despite more steps are involved in the overall synthetic route.  
 
Figure 2. General synthetic method for the synthesis of clofarabine [46].  
  
Figure 2. Reagents and conditions: (i) PNP, UP; (ii) BzCl, PyH, CH3CN; (iii) MeOH, Δ; (iv) Tf2O, PyH, 
CH2Cl2; (v) NEt3·3HF, NEt(iPr)2; (vi) MeONa, MeOH. 
 
The following two patent applications describe the preparation and the evaluation of 
anticancer activity in vitro of fluorinated pyrimidine nucleosides [54] and their silylated prodrugs 
[55]. The aim of the first invention patented in 2014 was to provide: a) methods for the preparation 
of fluorinated pyrimidine nucleoside analogs; and b) methods for inhibiting DNA methyltransferase 
and treating solid and hematologic cancers by these agents. The general synthetic route towards such 
modified nucleosides [54] consists of the typical coupling reaction between a sugar fragment (19) 
and an activated (silylated) nucleobase, namely 5-azacytosine, 2-hydroxypyrimidine and 5-
(trifluoromethyl)uracil. A number of fluorinated pyrimidine analogs such as 2’,2’-difluoro-5-
azadeoxycytidine (25), 2’,2’-difluorozebularine (26), 2’,2’-difluorodeoxyribose-trifluorothymidine 
(27) were prepared as reported in Figure 3. The 2’,2’-difluoro-5,6-dihydro-5-azadeoxycytidine 29 was 
prepared by treating the intermediate 22 with sodium borohydride in acetic acid followed by the 
removal of the benzoyl protecting groups from derivative 28 using a standard procedure.  
 
Figure 3. General synthetic route towards modified nucleosides [54]. 
 
 Figure 3. Reagents and conditions: (i) 19 [55], NEt3, toluene, (PhO)2POCl, 0°C to rt; (ii) HBr, acetic acid, rt; 
(iii) 19, MsCl [55]; (iv) nucleobase, (NH4)2SO4, HMDS, (CH3)3SiCl, reflux, anisole, SnCl4, 150°C to rt; (v) 
1M NaOMe, MeOH; (vi) TMSCl, NEt3, THF; (vii) NaBH4, acetic acid, rt. 
 
Among all the compounds tested, gemcitabine (4) revealed to be the most effective nucleoside in the 
inhibition of cell growth, exhibiting GI50 in the range of 0.01-0.72 µM in selected cell lines, including 
HCT-116 (colorectal) and breast (MDA-MB-231) cell lines, respectively. The gem-fluorinated 
analog of 5-azacytidine, the compound NUC013 (25), was found to be more active in comparison 
with its parent nucleoside 5-azadeoxycytidine in non-small cell lung and colorectal cell lines. 
The percent inhibition of DNA methyltransferase (DNMT) for selected compounds was calculated 
by using the DNA methyltransferase activity/inhibition assay in HT-116 cells treated with 5-
azacytidine and NUC013 (25) at two different drug concentrations for a period of 24 h. The results 
demonstrated that NUC013 (25) is an inhibitor of DNMT at both concentrations (1µM and 10µM), 
with a percent inhibition higher at 1 µM and comparable to its parent nucleoside 5-aza-C at 10 µM. 
The in vitro data (growth inhibition GI50) for the fluorinated (and non-fluorinated) nucleoside analogs 
are reported in Table 1. 
Table 1. GI50 in vitro data for the fluorinated and non-fluorinated nucleoside analogs [54]. 
 
Compound Structure NCI-H460 MDA-MB-
231 
HCT-116 HL-60 
Gemcitabine (4) 
 
0.02 0.72 0.01 0.03 
5-Azadeoxycytidine 
(decitabine) 
 
13.04 >31.25 >31.25 0.27 
5-Azacytidine 
 
0.43 1.64 0.62 0.44 
2’,2’-Difluoro-5-
azadeoxycytidine 
(25, NUC013) 
 
4.39 >31.25 4.54 1.51 
2’,2’-Difluoro-5,6-
dihydro-5-
azadeoxycytidine 
(29) 
 
4.84 >31.25 21.40 0.03 
2’-Deoxy-2’,2’-
difluorozebularine 
(26) 
 
135.65 165.9 310.26 - 
 
The aim of the second invention [55] was to provide a method for the preparation of prodrugs with 
prolonged circulatory half-life, thus providing anticancer therapeutics with potentially improved 
efficacy, safety, and/or pharmacokinetic profiles. In addition, formulating these hydrophobic 
molecules in a lipid-based nanoformulation would result in a rapid release of the active drug upon 
exposure to an aqueous environment at the tumour site. The introduction of a relatively non-toxic 
trimethylsilyl (TMS) group at the OH functional groups in the sugar moiety of selected NAs increases 
the hydrophobic nature of the prodrug, which is a prerequisite for further hydrophobic 
nanoformulation. The concept of incorporation of a bulky silyl group into 5’-OH position of 
nucleoside analogs was also applied in the antiviral field and led to the discovery of 5’-silylated 3’-
1,2,3-triazolyl thymidine analogs as inhibitors of West Nile Virus and Dengue Virus by binding to 
the viral methyltransferase (MTase) [57,58]. Moreover, the silylation strategy may potentially 
provide other benefits like for example enhanced permeability and retention (EPR), a property by 
which compounds with certain size tend to accumulate at a higher concentration in tumour rather than 
in normal tissues [59,60]. This is particularly important in the case of nucleoside analogs unstable in 
water such as 5-azacytidine, prone to fast hydrolytic cleavage of the nucleobase ring. Four fluorinated 
nucleosides were prepared based on the method reported in the earlier invention (Figure 3) [54]. In 
addition, two silylated prodrugs of 5-azacytidine and 2’,2’-difluoro-5-azadeoxycytidine (25) were 
further obtained by their treatment with an excess of trimethylsilyl chloride and trimethylamine in 
THF as shown in Figure 3 (step vi). This is a quite straightforward method that led to the formation 
of compounds 31 and 30, respectively. The latter silylated prodrug, although disclosed in the patent 
without in vitro data, was further successfully formulated in a nanoemulsion (at the concentration of 
3 mg/ml) and its toxicity was tested in mice. Animals were injected with the prodrug 30 (doses up to 
60 mg/kg) on three consecutive days and observed at the end of one week. No evidence of toxicity 
was shown as measured by weight loss up to the highest dose. The silylated prodrug (31) was tested 
in the in vitro cytotoxicity assay and showed comparable IC50 (µM) values with its parent nucleoside 
5-azacytidine (Table 2). The inventors postulated that silylated 5-aza-nucleoside analogs prodrugs 
may potentially demonstrate superiority in vivo, where a longer circulating half-life is crucial. 
 
Table 2. In vitro cytotoxicity of NUC025 (31) and 5-azacytidine (IC50 in µM) [55]. 
 
Compound Structure Cell lines 
MDA-MB-231 HCT-116 L1210 
NUC025 (31) 
 
3.28 1.08 1.18 
5-Azacytidine 
 
1.64 0.62 1.7-2.4 
2’,2’-Difluoro-5-
azadeoxycytidine-
trimethylsilyl (30) 
 
ND ND ND 
 
ND - no data reported 
 
Fluorinated nucleosides in antiviral therapy 
Nucleoside analogs constitute a fundamental family of compounds used as antivirals, as most 
therapies against extremely important human pathogens are based on the administration of nucleoside 
agents, including the treatment strategies for herpes simplex virus (HSV), varicella zoster virus 
(VZV), human cytomegalovirus (HCMV), human immunodeficiency virus (HIV) and hepatitis B 
virus. With some exceptions, these compounds usually exert their antiviral effect by inhibiting an 
essential step in the virus life cycle, the replication of the viral genome, by targeting the viral 
polymerase (pol) or reverse transcriptase (RT) enzymes. The active form of these nucleosides 
targeting the viral nucleic acid synthesis is the 5'-triphosphate species. As in the case of anticancer 
nucleosides, different prodrug strategies have been developed to deliver the nucleoside 
monophosphate into the infected cells, as the rate-limiting step for the activation of nucleoside 
analogs to their triphosphate forms is the first phosphorylation into the monophosphate species. As a 
means to significantly improve their biological profiles and metabolic properties, fluorine is present 
in the structures of different antiviral nucleosides currently approved or in clinical trials. Fluorine-
containing antivirals or candidate antivirals show the presence of this halogen both at the nucleobase 
level and at the sugar level, as highlighted in Figure 4, which summarises FDA-approved fluorinated 
antiviral nucleoside analogs (5, 32-34) and the main antiviral candidates in clinical development 
belonging to this class (35-40). 
Figure 4. Fluorinated antiviral nucleosides in the market or in advanced stages of clinical trials. 
 
 
The first approved fluorinated antiviral nucleoside was trifluridine (TFT, 5), which is an anti-herpes 
virus drug approved in 1980 and it is used mainly as eye-drops to treat keratitis and kerato-
conjunctivitis associated with herpes simplex 1 and 2 infections to the eye [61]. In combination with 
the thymidine phosphorylase inhibitor tipiracil, trifluridine is also used for the treatment of metastatic 
colorectal cancer [22,23,62]. Another noteworthy fluorinated nucleoside is emtricitabine (FTC, 32), 
a fluorinated analog of the L-nucleoside lamivudine (3TC), FDA-approved in 2003 for the treatment 
of HIV infection. FTC acts as a nucleoside reverse transcriptase inhibitor (NRTI) and it is part of 
several fixed-dose combination drugs approved to control and prevent the infection, such as Atripla, 
Stribild, Sustiva, Descovy and Truvada [63]. Due to its fundamental role in highly active antiretroviral 
therapy for HIV, FTC is included in the WHO’s list of essential medicines [64]. 
One fluorinated nucleotide prodrug that has revolutionised antiviral therapy in the case of hepatitis C 
virus (HCV) is sofosbuvir (33), a nucleoside phosphoramidate (ProTide) whose active species 
potently inhibits the HCV NS5B RNA-dependent RNA polymerase [65]. Before the first direct-acting 
antiviral agents, HCV protease inhibitors were introduced, HCV management was non-specific for 
the virus and effective only in 50% of infected patients; these protease inhibitors, however, were 
genotype-specific and associated with severe side-effects and the insurgence of drug-resistance [66]. 
The approval of sofosbuvir in 2013 has completely changed the perspectives for HCV treatment: this 
is the first anti-HCV drug to show antiviral activity across all main genotypes of the virus, and when 
administered in combination with protease inhibitors and/or multifunctional NS5A enzyme 
inhibitors, it leads to complete clearance of the virus in most treated patients, providing the basis for 
all-oral, interferon-free treatments that have made possible to cure chronic hepatitis C [67]. 
Another fluorinated nucleobase analog in the market as antiviral is favipiravir (T-705, 34), approved 
in 2014 in Japan as a measure to prevent influenza pandemics [68]. Due to its pyrazine structure, T-
705 acts as a pseudo-base and, mimicking a purine analog, it is converted into the ribofuranosyl 5’-
triphosphate metabolite, inhibiting the virus RNA-dependent RNA-polymerase [69]. Since its 
discovery, different additional mechanisms such as lethal mutagenesis have been reported to 
contribute for its antiviral effect [70], and these multiple ways to interfere with viral replication might 
be at the basis for the broad-spectrum antiviral activity of this compound, which shows an antiviral 
effect against different emerging and re-emerging RNA viruses such as Chikungunya virus, Zika 
virus and, most importantly, Ebola virus [71]. 
Several fluorinated antiviral candidates are also in advanced clinical trial stages. Among them 
mericitabine (35) and GS-0938 (36) reached Phase II clinical trials for the treatment of HCV [72]. 
However, further clinical development of these two agents has been terminated due to a lack of 
significant clinical benefits [73,74]. Both these nucleoside analogs target the viral NS5B polymerase 
in their active triphosphate forms, and they represent different prodrugs of the same 2’-methyl, 2’-
fluoro ribose sugar present in sofosbuvir, differing for the nucleobase, cytidine in mericitabine (35) 
and protected guanine in GS-0938 (36), respectively. PSI-353661 (37), which is in pre-clinical 
development for the treatment of HCV, is characterised by the same fluorinated nucleoside template 
of GS-0938, but shows the presence of a phosphoramidate prodrug moiety at the 5’-sugar position 
[75]. 
Other fluorinated nucleoside analogs under investigation include fiacitabine (38), in Phase II trials 
for human cytomegalovirus (HCMV) and HIV infections, and elvucitabine (39), in Phase II trials as 
HIV agent, which also displays potent activity against HBV [76]. Finally, GS-9131 (40) is the amidate 
prodrug of a nucleoside 5’-phosphonate, characterised by a 2’-fluoro-2’,3’-unsaturated sugar, in Phase 
II clinical trials for the treatment of HIV [77]. 
 
 
 
 
Antiviral fluorinated nucleosides or methods for their preparation in recent patent literature 
The most recent patent on antiviral fluorinated nucleosides has been filed in September 2017 by 
Andrei et al., and it concerns the preparation of novel acyclic nucleoside phosphonates as antiviral 
agents to treat or prevent HBV, HIV, HCMV and VZV [78]. The authors describe the preparation of 
novel phosphonoamidate prodrugs of acyclic nucleoside phosphonates with a 3-fluoro-2-
(phosphonomethoxy)propyl side chain, and the evaluation of their antiviral activities against the four 
viruses mentioned above. As depicted in Figure 5, the novel compounds exemplified include the 
natural thymidine, adenine, cytosine and guanosine nucleobases, along with 2-amino-6-(4-methoxy-
thiophenol)purine, 7-deaza-guanine, 7-deaza-7-fluoroguanine and 7-deaza-7-cyano-guanine. Once 
the nucleobase is functionalised with the acyclic fluorinated phosphonate ester 41 and the two ester 
groups are cleaved to yield the corresponding free phosphonic acids, as shown in Figure 5, the free 
acids are then converted into the corresponding aryloxyphosphonamidates (42-50). 
Figure 5. General synthetic route towards aryloxyphosphonamidates 42-50 [78]. 
 Figure 5. Reagents and conditions: (i) PPh3, DIAD, THF, rt, 24 h; (ii) TMSBr, 2,6-lutidine, CH3CN, rt, 12 h; 
(iii) L-aspartic acid amyl diester HCl salt, PhOH, 2,2’-dithiopyridine, PPh3, NEt3, Pyr, 60 °C, 12 h [78]. 
 
All the diastereomeric mixtures at the 3-(fluoropropan-2-yl)oxy)methyl chiral carbon have been 
separated, the two diastereoisomers for each couple have been evaluated against HBV, HIV, HCMV 
and VZV replication in cellular systems, and potent inhibitors of the viral replications have been 
identified among these new fluorinated analogs, which also appear to be non-toxic and show high 
selectivity indexes. The most significant antiviral data are reported in Table 3. In most cases, the 
chirality on the 3-(fluoropropan-2-yl)oxy)methyl chiral carbon is key for antiviral activity, as there is 
a marked difference in the antiviral potential for all S/R diastereomeric couples at this carbon. 
Table 3. Antiviral and cytotoxicity data for the most active novel analogs reported by Andrei et al. 
[78]. 
Compound Structure Virus EC50 (µM) CC50 (µM) 
3TC (Lamivudine) 
 
HBV 0.02 >2.00 
Entecavir 
 
HBV <0.01 >1.00 
43 (S) 
 
HBV 
 
HIV-1 
0.01 
 
0.01 (X4 strain NL4.3) 
0.0042 (R5 strain BaL) 
22.56 
 
33.21 
43 (R) 
 
HBV 
 
HIV-1 
1.06 
 
0.14 (X4 strain NL4.3) 
0.11 (R5 strain BaL) 
33.03 
 
37.61 
45 (S) 
 
HBV 
 
HIV-1 
0.13 
 
0.16 (X4 strain NL4.3) 
0.22 (R5 strain BaL) 
>100 
 
>100 
45 (R) 
 
HBV 
 
HIV-1 
0.02 
 
0.073 (X4 strain NL4.3) 
0.06 (R5 strain BaL) 
>100 
 
>100 
44 (S) 
 
HCMV 
 
 
VZV 
0.76±0.10 (AD-169 strain) 
2.02 (Davis strain) 
 
3.15±2.61 (Oka strain) 
1.32±0.46 (strain 07-1) 
74.7±9 
44 (R) 
 
HCMV 
 
 
VZV 
>32.6 (AD-169 strain) 
>32.6 (Davis strain) 
 
>32.6 (Oka strain) 
>32.6 (strain 07-1) 
ND 
50 (S) 
 
HCMV 
 
 
VZV 
17.6±4.3 (AD-169 strain) 
16.2±2.3 (Davis strain) 
 
3.96±1.147 (Oka strain) 
1.32±1.50 (strain 07-1) 
46.9±2.20 
50 (R) 
 
HCMV 
 
 
VZV 
0.029±0.0046 (AD-169 strain) 
0.033±0.0081 (Davis strain) 
 
0.034±0.026 (Oka strain) 
0.013±0.0096 (strain 07-1) 
>163 
Ganciclovir 
 
HCMV 
 
 
VZV 
8.70±0.66 (AD-169 strain) 
16.25±22.5 (Davis strain) 
 
ND 
>391 
Brivudin 
 
HCMV 
 
 
VZV 
ND 
 
 
0.055±0.019 (Oka strain) 
5.21±3.97 (strain 07-1) 
>300 
 
Two recent patents on antiviral fluorinated nucleosides are focussed on the preparation of the 
blockbuster anti-HCV drug sofosbuvir (33). The first, filed by Sandoz in 2016 [79], protects an 
improved fluorination method for the preparation of sofosbuvir-based nucleoside starting from 2’-C-
methyl-arabino-uridine 51, which is prepared according to a reported procedure [80]. As shown in 
Figure 6, different protecting groups are explored in this patent for the protection of the 3’- and 5’-
positions of the starting nucleoside, and on these protected molecules an alternative deoxyfluorinating 
agent is used to achieve deoxyfluorination in position 2’: XTalFluor E, 
(diethylamino)difluorosulfonium tetrafluoroborate, is used as the fluoride source. This 
tetrafluoroborate salt replaces DAST, used in the previous art, and it is associated with a significantly 
improved fluorination yield on the nucleoside substrate when applied together with the alternative 
protecting group, CCl3CO, introduced for the first time in the invention, as summarised in Table 4. 
Figure 6. Synthetic method for the preparation of sofosbuvir-based nucleoside 55 and sofosbuvir (33) 
[79]. 
 Figure 6. Reagents and conditions: (i) NEt3, TEA·3HF, DCM, rt, 4 h [79]. 
 
Table 4. Yields of desired products 53 and undesired unsaturated by-products 54 in the presence of 
different protecting groups for the nucleoside substrates and different deoxyfluorinated agents, 
DAST, as per the previous art, and XTalFluor E, as presented in the invention. [79] 
Protecting group (R) Deoxyfluorinating agent Yield % of target 
compound 53 
Yield % of 
unsaturated 54 
CF3CO XTalFluor E 42 % (deprotected) 37% (deprotected) 
CH3CO XTalFluor E <26% (protected, not 
isolated) 
N.D. 
CH3CO XTalFluor E <26% (protected, not 
isolated) 
N.D. 
ClCH2CO XTalFluor E 47% (protected) 24% (protected) 
CCl3CO XTalFluor E 46% (after 
deprotection) 
58% (no deprotection) 
N.D. 
CCl3CO DAST <20% (protected, not 
isolated) 
N.D. 
CH3SO2 XTalFluor E 26% (protected) 63% (protected) 
t-Bu-CO XTalFluor E 18% (protected) 7% (protected) 
Ph-CO XTalFluor E 12% (protected) 2% (protected) 
Ph-CO DAST 20% (protected) 42% (protected) 
 
A second Chinese patent filed in 2017 describes an alternative method for the preparation of 
sofosbuvir starting from β-D-ribose and using, according to the inventors, cheaper raw materials and 
synthetic methods in comparison with the previous art [81]. The proposed economic and easy to scale-
up strategy is composed of eight synthetic steps from β-D-ribose, as shown in Figure 7. 
Figure 7. Economic and easy to scale-up strategy for the preparation of sofosbuvir (33) [81]. 
 
Figure 7. Reagents and conditions: i) Acetyl chloride, MeOH, 0 °C to rt, 24 h; ii) TIPDSCl, DCM, Pyr, 0 °C 
to rt, 3 h; iii) PhMe, EtOAc, TEMPO, aq. NaHCO3, NaOCl, 0 °C, 2 h; iv) MeMgCl, Et2O, 0-10 °C, 3 h; v) 
DAST, DCM, THF, rt, 3 h; vi) SnCl4, MeCN, 0 °C to rt, 4 h; vii) DMF, glacial AcOH, NMe4F, rt, 2 h (95%); 
viii) tert-BuMgCl, THF, rt, 48 h (68%) [78]. 
 
Briefly, in this synthetic strategy, the 1’-hydroxyl function of β-D-ribose is converted to methoxy 
using acetyl chloride in methanol (Figure 7, step i). This substrate (57) is then protected with a 
tetraisopropyldisiloxane group at the 3’- and 5’-positions, and the free hydroxyl group in 2’ is then 
oxidised to ketone using sodium hypochlorite and TEMPO (Figure 7, steps ii and iii). The 2’-keto 
intermediate (59) is then treated with a Grignard reagent to afford the methylation at the 2’-position, 
and this methylated sugar (60) is then fluorinated in 2’ using DAST (Figure 7, steps iv and v). The 
2’-methyl-2’-fluoro protected sugar (61) is then coupled with silylated uridine in anhydrous 
acetonitrile using tin (IV) chloride as Lewis acid. The silylated nucleoside (62) is deprotected using 
acetic acid and tetramethylammonium fluoride, and the free key nucleoside 55 is finally reacted with 
(2S)-2-(((4-ylphenoxy)phenoxyphosphoryl)propionic acid isopropyl ester in tetrahydrofuran using 
the strong Grignard reagent tert-butylmagnesium chloride as base to give sofosbuvir (33). Even if the 
authors claim that this represents an improved method for the preparation of sofosbuvir, no 
comparison with the previous art is possible, based on the data provided as examples in the document: 
reaction yields are given only for the two last steps of the synthetic scheme, no indication is present 
on the anomeric selectivity of the methylation and fluorination steps, and no information is given on 
how the sugar with the desired configuration at the 2’-position is isolated, and what is the yield of the 
desired sugar configuration over the other. 
Over the last five years a number of patent applications enclosing procedures for the 
diastereoselective preparation of sofosbuvir with high purity level and improved yield, physical and 
chemical properties were reported, as summarized in Table 5 [82-85]. In general, methods disclosed 
in these patents are based on novel synthetic schemes and use of novel intermediates and 
phosphoramidating agents employed in the preparation of sofosbuvir.  
Table 5. Methods for the preparation of sofosbuvir-related patent applications.  
Patent application number and title Context of the disclosure  Ref 
WO 2017/009746 
“An improved process for the preparation 
of sofosbuvir” 
Use of a novel reagent (magnesium di-tert 
butoxide instead the standard tBuMgCl) as a 
base for the coupling reaction (Figure 7, step 
viii) 
Use of novel type of oxyimino-
phosphoramidating reagents for the coupling 
reaction (Figure 7, step viii) 
[82] 
WO 2017/093973 
“Process for the preparation of pure 
sofosbuvir” 
Use of “bromo-sofosbuvir” as an intermediate 
compound to obtain sofosbuvir 
 
[83] 
WO 2016/008461 
“A new form of sofosbuvir and a method 
for its preparation” 
New polymorphic form of sofosbuvir, its 
preparation and characterisation  
[84] 
US  2016/0318966 
“Process for the preparation of sofosbuvir” 
Use of protected nucleoside intermediate and a 
single diastereomer phosphoramidating reagent 
[86] for the coupling reaction (Figure 7, step 
viii) 
[85] 
The term “bromo-sofosbuvir” refers in the patent [83] to (S)-isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-
dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltatrahydrofuran-2-yl)-(4-
bromo-phenoxy)phosphorylamino)propanoate.  
 
 
 
Antiviral nucleotide prodrugs 
The concept of phosph(on)ates prodrugs and aryloxyphosphoramidates (ProTides) in particular, as a 
technique to confer better efficacy profiles to nucleoside analogs, was extensively investigated for 
the last three decades [22,44,87]. This technology, which has been extensively applied to several 
different modified nucleoside with both antiviral and anticancer properties, continues to be of great 
scientific interest. A considerable amount of patent inventions directed to methods of synthesis and 
use of phosph(on)ates prodrugs was published in the literature [88-93]. Due to a limited scope of the 
present review and its main focus on fluorinated nucleosides, in this section only selected and most 
recent patent applications are briefly highlighted with general examples of fluorinated-nucleos(t)ide 
analogs disclosed, as reported in Table 6. 
Table 6. Selected patent applications disclosing methods for the preparation of nucleoside and 
nucleotide analogs thereof [88-93].  
Patent number and title 
 
Context of the disclosure  
 General formula of compound(s) disclosed 
Ref 
US 2015/0366888 A1 
“Substituted nucleosides, nucleotides 
and analogs thereof” 
Synthesis of fluorine-containing nucleosides 
and their nucleotide analogs and methods for 
the treatment of diseases and/or conditions of 
viral infection caused by Coronaviridae virus, 
a Togaviridae virus, a Hepeviridae virus.   
 
[88] 
WO 2016/178876 A9 
“Nucleoside analogs for treatment of 
the Flaviviridae family of viruses and 
cancer”  
Synthetic methods for the preparation of 
nucleosides and their nucleotide analogs. 
Methods for treating and preventing 
Flaviviridae family of viruses, RSV, HEV, 
and influenza infection and cancer in human 
subjects or other animal hosts. 
[89] 
  
WO 2016/140615 A1 
“Nucleotide derivatives which are 
HCV inhibitors for use in the treatment 
of hepatitis C” 
Synthetic methods for the preparation of 
nucleoside (1-((2R,3S,4R,5R)-3-chloro-3-
fluoro-4-hydroxy-5-(hydroxymethyl)-
tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-
dione and its phosphoramidate prodrug  
represented by formula 3. Use of the prodrug 
(formula 3) in the treatment or prophylaxis of 
hepatitis C, including HCV genotype 3 virus 
infection in a combination therapy. 
 
[90] 
US  2017/0037078 A1 
“2’-Disubstituted nucleoside analogs 
for treatment of the Flaviviridae family 
of viruses and cancer” 
Synthetic methods for the formation of 2’-
disubstituted nucleoside analogs and 
nucleotide prodrugs and their use to treat and 
prevent Flaviviridae infections, RSV and 
influenza infection and cancer. 
  
[91] 
US 2017/0057981 A1 
“Anti-viral compounds” 
Processes for the preparation of nucleoside 
and nucleotide analogs and their use for the 
[92] 
treatment of HCV infection. 
 
WO 2017/053216 A2 
“4’-Substituted nucleoside reverse 
transcriptase inhibitors and 
preparations thereof” 
 
Methods for the preparation of fluorinated-
nucleosides and their nucleotide analogs as 
inhibitors of HIV reverse transcriptase. 
 
[93] 
 
Recent patent literature on fluorinated nucleosides with miscellaneous uses, or 
methods for their preparation 
As discussed above, several 18F-fluorinated nucleosides are under clinical investigation as probes for 
positron emission tomography (PET), in order to be used as biomarkers for cell proliferation in 
oncology, as imaging tracers for personalised medicine formulations, and as tools to predict the 
patient’s response to nucleoside-based chemotherapy [94]. As the 18F-fluorine needs to be 
incorporated at a late stage in the synthesis of these probes, in order for the synthesis and the imaging 
steps to be performed in the timeframe of multiple half-lives, thus resulting in scanning data of high 
quality, the chemistry for its introduction, usually based on aliphatic nucleophilic fluorinations on the 
protected nucleoside, is renowned as challenging, time consuming, labour intensive, highly variable 
and unreliable. In order to introduce the labelled fluorine late in the synthesis, preparation of activated 
fluoride (moisture-free) is required: traces amounts of 18F-fluoride are sequestered into anion 
exchange columns, then eluted using salts dissolved in water, and finally dried from the excess water 
in order to afford an activated mixture of 18F-fluoride, salt (usually K2CO3) and a stabilising agent 
such as Kryptofix K222. The dried mixture is then used for the labelling of the probe. This drying step 
is usually time-consuming, it requires elevated temperatures, and it can lead to under-drying or over-
drying, which both affect negatively the labelling step. In 2015, a patent was granted on the 
preparation of 18F-labelled tracers in hydrous organic solvent mixtures that, containing between 0.1% 
and 5.0% of water, do not require drying of the activated 18F-fluoride mixture, thus speeding-up the 
process of labelling and increasing the yields of radiolabelled probes, as the activated 18F-fluoride 
organic solution can be used directly for the radiolabelling step [95]. The patent exemplifies, among 
others, the preparation of 18F-FLT, the first 18F-radiolabelled approved for human use as tracer for 
tumour proliferation [96-99], as shown in Figure 8: the 18F-labelling step occurs in high yield from 
the protected precursor Boc-Boc-Nos, with a precisely controlled amount of water and no drying step 
required. 
Figure 8. Synthetic method to prepare 18F-FLT [95]. 
 
Figure 8. Reagents and conditions: i) K2CO3, Kryptofix-[222], [18F]-Fluoride, MeCN, 135 °C, 180 sec; ii) 1M 
HCl, 105 °C, 600 sec. [95]. 
 
As reported in the patent, the first reaction step is monitored via radio-TLC, which indicates a >90% 
conversion of the 18F-fluoride into 18F-Di-Boc-FLT (64). Subsequent Boc-deprotection in aqueous 
HCl yielded the desired FLT (65) with a >96% purity. 
Another worth-mentioning patent is focussed on the radio-synthesis of fluorinated pyrimidine 
nucleosides (filed in 2012 by Li et al.) [100], represented by 18F-FMAU (69), an established PET 
probe used to monitor cellular proliferation [101,102]. The inventors reported an improved method 
of one-pot procedure to synthesize 18F-FMAU. Furthermore, the claimed method can also be 
incorporated into a fully automated cGMP-compilant radio-synthesis module to produce PET probes 
by simplified reaction conditions in the presence of Friedel-Crafts catalysts. These 18F-labelled 
thymidine or cytidine analogs can also be used as PET tracers for certain medical conditions including 
autoimmunity inflammation and bone marrow transplant [103]. The authors discuss various reaction 
conditions (solvents, reaction temperature, the use of different Friedel-Crafts catalysts: AlCl3, SnCl4, 
ZnCl2 and TMSOTf), and their influence on the conjugation (Figure 9, step ii), yield and ratio of α/β 
anomer formation for the compound 68 (Figure 9). TMSOTf was claimed as the most efficient 
catalyst acting also as a co-solvent, significantly improving a solubility of the silylated-base, the yield 
of the coupling step, and increasing the formation of the desired β-anomer. In addition, alternative 
methods/platforms that are suitable for the synthesis of radiopharmaceuticals such as microwave-
assisted conjugation and microfluidic devices are mentioned in the patent, as they can be also used in 
the preparation of 18F-radiolabelled nucleoside analogues exemplified in the patent with the potential 
to increase radio-synthesis output. 
Figure 9. Synthetic method for the preparation of 18F-FMAU [100]. 
 
Figure 9. Reagents and conditions: (i) 18F-NBu4F, MeCN, 80 °C, 30 min. (ii) TMSOTf, HMDS (iii) NaOMe, 
MeOH then HPLC purification [100]. 
Examples of other [18F]-labelled 5-substituted thymidine analogs which synthesis can be carried out 
with a full one-pot automation are depicted in Figure 10.  
Figure 10. Examples of 18F-labelled 5-substituted thymidine analogs 70-75 [100]. 
 
 
 
The recent patent focusing on the preparation of modified RNAi agents containing 2’-fluoro or 2’-
methoxy-xylose analogs of natural nucleosides, and their use as modulators of gene expression, was 
filed in 2014 by [104]. RNA interference (RNAi) is the effect of the administration of double-stranded 
RNA (dsRNA), which can block gene expression: short dsRNA are responsible for gene-specific 
post-transcriptional silencing in several organisms, and the reduced expression of selected target 
genes is correlated with several effects, such as increased host immune response against pathogens, 
increased expression of genes implicated in cell cycle arrest, increased expression of tumour 
suppressor genes. As a chemical modification to dsRNAs to improve their drug-like properties, this 
patent protects the preparation of double-stranded RNAi agents with 12 to 30 nucleotides in the sense 
strand and antisense strand, which contain at least one xylo-modified or 2’-modified nucleoside with 
a fluoro or a methoxy group. The fluorinated nucleosides included in the invention as building blocks 
for modified dsRNAs are shown in Figure 11. 
Figure 11. Modified fluorinated nucleosides inserted by Rajeev et al. in the sequences of dsRNAs 
[104]. 
 
 
 
Following a discussion of methods to prepare the target dsRNAs with the described modifications, 
the inventors also disclosed the improved stability of such structures towards snake venom 
phosphodiesterase and their activity against the blood coagulation factor VII in mice: the novel 
dsRNAs display IC50 values between 0.0074 nM and 0.1822 nM. 
In 2013, Barthelemy et al. have protected the use of fluorinated amphiphilic glycosyl nucleosides 
(GNFs) as supramolecular systems comprising low molecular weight molecules for decontaminating 
aqueous mediums from nanoparticles and microparticles, with an exemplified focus on gold 
nanoparticles (auNPs), which is an important contaminant in the cosmetic industry [105]. This 
invention describes the use of supramolecular systems for subtracting particles from a liquid medium, 
mainly water, and these supramolecular systems are made of at least one low-molecular weight 
molecule together with organic polymers such as collagens, polysaccharides or proteoglycans. The 
patent protects several fluorinated and perfluorinated molecules as depicted in Figure 12, but the only 
one exemplified is the compound 83, whose synthesis had been previously published in Tetrahedron 
Letters in 2010 [106]. 
Figure 12. Fluorinated amphiphilic glycosil nucleosides considered by Barthelemy et al. for the 
hydrogel-based decontamination of aqueous media [105]. 
  
 
In 2016, Ptacin et al. have protected the preparation of oligonucleotides with an expanded genetic 
alphabet, including several unnatural bases, unnatural sugars and also modified linkers between 
nucleosides [107]. Different of the unnatural modifications protected in this application contain 
fluorinated groups, and they are summarised in Figure 13. 
Figure 13. Fluorinated unnatural bases and sugars protected by Ptacin et al. as building blocks for 
the preparation of mutant tRNAs and mRNAs [107]. 
 
 Figure 13. Fluorinated unnatural bases and sugars protected by Ptacin et al. as building blocks for the 
preparation of mutant tRNAs and mRNAs [107]. 
 
These unnatural bases and sugars are claimed to be used in the preparation of mutant tRNAs and 
mRNAs, according to a series of several mutant codon (tRNA) and anticodon (mRNA) sequences 
described in the application. These mutant tRNAs and mRNAs are then used to synthesise unnatural 
amino acids, which are also exemplified in the patent application. The claimed therapeutic uses of 
the protected method are the generation of probes, unnatural polypeptides, unnatural macrocycles, 
site-specific antibody-drug conjugates, bi-specific antibodies, nucleic acid catalysts, biosensors, kill 
switch and gene delivery. Even if all these applications are claimed and the preparation of the mutant 
tRNAs and mRNAs is described, no example is given on any practical use, and efficacy, of the 
protected unnatural nucleic acids and amino acids. 
One final patent application filed in 2016 [108] describes the preparation of novel fluorinated 
deoxyribo-cyclic dinucleotides (CDNs) and evidences their activity as activators of the receptor 
STING (stimulator of interferon genes) [109,110]. By activating this receptor, the novel compounds 
are demonstrated to induce the production of Type I interferons and pro-inflammatory cytokines, 
which represents a very promising approach for immunotherapy, to enhance the immune system’s 
responses of a human or animal in the case of autoimmune disorders, immune system deficiencies, 
bacterial or viral infections, other infectious diseases, or cancer. The novel fluorinated compounds 
protected in this invention, whose structures are summarised in Figure 14, show improved biological 
and pharmacokinetic properties in comparison with their non-fluorinated analogs, as demonstrated in 
the patent. 
Figure 14. Summary of the structures protected by Vernejoul et al. as STING agonists [108]. 
 
 
 
The patent also describes in detail the chemical preparation of the novel immunotherapy agents 
exemplified. A summary of the exemplified structures, for which extensive biological data are also 
reported in the application, is given in Figure 15. 
Figure 15. Compounds exemplified by Vernejoul et al. as STING agonists [108]. 
 
  
Cytokine induction in treated cell cultures has been determined for the exemplified new compounds 
using different cell lines, and they were confirmed to induce Type I interferons production in wild-
type cells but not in STING knockout cells, confirming that they act through the activation of STING. 
The in vitro assays also confirm that the fluorinated analogs prepared are more active than the 
corresponding reference compounds. Cytokine induction is also evaluated in vivo in mice models, 
and the ability of the new CDNs to induce Type I interferons is confirmed. This activity is also 
determined in vitro in whole human blood from healthy donors, and also in this case their ability to 
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induce different cytokines is confirmed, with the fluorinated analogs showing an improved activity 
in comparison with their non-fluorinated counterparts. Finally, the fluorinated deoxyribo-CDNs are 
shown to be more resistant to enzymatic degradation by snake-venom phosphodiesterase (SVPD) and 
nuclease P1 (NP1) than the non-fluorinated analogs. 
 
Future perspective 
Nucleoside analogs, commonly known as antimetabolites, constitute a fundamental class of 
chemotherapeutic agents widely used in the clinic for many decades. Among them, fluorine-modified 
nucleosides are a very important class of anticancer and antiviral drugs. In this review we presented 
fluorine-containing nucleoside analogs, their methods of synthesis and therapeutic use that have been 
the subject of recent patent applications. Therefore, the main areas of focus were synthetic procedures 
for the preparation of selected fluorinated nucleosides such as anticancer clofarabine, gem-fluorinated 
5-azacytidine analogs and 18F-labeled agents FLT and FMAU used in the clinic as PET tracers. As 
the synthesis of 18F-labeled nucleoside-type agents is challenging, over the past years a significant 
effort was made to develop improved effective strategies for the preparation of such agents. Herein, 
we also outlined current developments and processes for the preparation of blockbuster anti-HCV 
drug sofosbuvir, which may be considered industrially amenable. In addition, we emphasized 
examples of patent inventions directed towards synthesis and biological applications of 
phosphoramidate prodrugs based on fluorinated-nucleosides. A number of other therapeutic 
applications of fluorine-containing nucleosides are highlighted with modified RNAi agents 
containing 2’-fluoro or 2’-methoxy-xylose analogs as potential modulators of gene expression or 
novel fluorinated deoxyribo-cyclic dinucleotides (CDNs) as activators of receptors of STING 
signalling pathway. Due to the enhanced pharmacokinetic and pharmacodynamics profiles that 
fluorine can induce in drug-like molecules, the substitution of structural hydrogen atoms with fluorine 
will continuously be applied in medicinal chemistry programs as a powerful tool to improve key drug-
like features. As the nucleos(t)ide analogs are considered as cornerstone in the treatment of viral and 
cancer diseases, and there is a continuous need for novel and more effective agents, further 
modifications of nucleosides including fluorination are likely to continue and remain a rich source of 
patent literature.  
 
Executive summary: 
 
  Insertion of fluorine in the structures of established bioactive nucleosides has resulted in the 
approval of several new drugs with both antiviral and anticancer therapeutic scopes. 
 The fluorine atom, with its unique characteristics, has a pivotal role to alter a variety of 
physicochemical properties of drug-like molecules, thus influencing their molecular stability 
and target binding properties.  Recent patent applications on fluorine incorporation chemistry using nucleophilic fluoride 
have greatly influenced the continuously evolving 18F-PET radiochemistry.  Examples of recent patent applications disclosing improved methods for the preparation of 
anticancer fluorine nucleosides and prodrugs are discussed within the anticancer nucleosides 
section.  Examples of recent patent applications reporting on improved/alternative methods for the 
preparation of anti-HCV agent sofosbuvir and novel acyclic nucleoside phosphonates are 
discussed within the antiviral nucleosides section. 
 Examples of fluorinated nucleosides with miscellaneous uses and methods for their 
preparation based on the recent patent applications are provided in this review. 
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